Further exploration into the long-term impacts of these interventions, including differences between medications, on patient adherence and health outcomes would provide deeper insights into the chronic management of obesity and type 2 diabetes with GLP-1 RAs. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.